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How to stay ahead in the race against resistant pathogens 
TREATMENT SETTING 
- Rapid species identification and antibiogram  
• for serious infections (e.g., BSIs) 
• for patients at risk (e.g., traveled/admitted from ≠ countries, in ICU) 
• enable effective antibiotic stewardship interventions 
- Rapid detection of key resistance mechanisms or genes  
• ESBLs and carbapenemases 
• affecting other key antibiotics (e.g., polymyxins) 
- Rapid MIC values for key antibiotics 
• Cefepime, carbapenems, polymyxins ……. 
HOSPITAL HYGIENE SETTING 
- Rapid screening to identify patients colonized with MDR bacteria 
 for isolation (prevention of outbreaks, save costs) 
- Rapid identification of clonal MDR strains 
 identifying sources, tracking dynamics, intervention 
- Microbiological lab data and algorithms * 
Isolation 
Outcome 
Directed  
treatment 
Empirical  
treatment 
+ 
Standard culture approach 
Even more days to get the final 
report including resistance 
mechanism(s)/gene(s) 
Septic shock  
Inappropriate antibiotic use within the 
first 6 hours is associated with a 5- fold 
higher mortality risk  
[Kumar A et al., Chest, 2009] 
 
BSIs 
Mean decrease in survival of 7. 6% for 
each hour after the onset of BSI until 
initiation of effective antibiotics 
[Kumar A et al., Crit Care Med, 2006] 
 
MDR Gram- neg BSI 
It costs 30. 000 $ more (1 1  vs.  6 days 
of hospitalization)  
[Schwaber MJ et al., JAC, 2007]  
 
ID/AST 
Still 
standard 
Theparee T et al., JCM Nov 8, 2017 
Bruker MALDI-TOF MS (Oct, 2013) - BD Kiestra TLA (Dec, 2014) 
STUDY AIM: TAT for +/- urine cultures before and after implementation   
Comparison I:  
Impact of Kiestra TLA 
Comparison II:  
Impact of MALDI and/or Kiestra TLA 
Future developments on lab automation 
Automated colony picking for ID and AST (e.g., MaldiTofA and Colibri) 
Automated disk diffusion AST preparation 
Automated inhibition zone measurements 
Expert systems for dynamic AST interpretation 
SMART IMCUBATORS MALDI-TOF MS 
Digital image of automated direct screening for resistance (5 hrs) 
E.  coli, AMP=R E.  coli, ESBL+ 
AST Enterobacteriaceae at 5 hrs vs.  VITEK2 AST P.  aeruginosa at 8 hrs vs.  VITEK2 
BACTEC 
187 +BCs for G- 
2 drops in  
Copan ESwab 
Kiestra InoqulA 
MH plates 
Pre-loaded disk 
stamp 
Kiestra InoqulA 
MH plates 
Kiestra ReadA 
incubators  
15 min 
BD ReadA  
Browser software 
(Inhib. zone marked manually) 
82.8% were evaluable at 4 hrs 
Ideal system 
• Species identification (ID) 
• AST (MIC) and interpretation (S, I, R) 
• Genes and/or resistance mechanisms 
• Kit and automated (easy to use) 
• High sensitivity/specificity 
• Clinical samples (or at least +BCs) 
• Rapid  
• Cost-effective 
Amplex Eazyplex 
• Preparation (5 min) 
• No DNA extraction/purification 
• Run time (<30 min) 
Version A Version B 
LAMP 
Loop-mediated isothermal Amplification 
 
Real-time fluorescent measurement 
Genie II platform 
~55 Euro 
Rödel J. et al., Eur J Clin Microbiol Infect Dis; 2017 
ID § 
Resistance 
In-house LAMP assays (not available) 
Time to 
results 
Germany, 2015 
370 +BCs (of which 140 G+) 
Test preparation from 25 µL of +BC: 5-10 min 
From +BC ~30 min 
Verigene, Nanosphere 
• Load cartridge, consumables, and sample (5 min) 
• Automated sample preparation and processing 
• Place slide from cartridge in reader (2.5 hrs) 
Gram-negatives cartridge Gram-positives cartridge 
Microarray approach by 
using Au-nanoprobe as 
reporter and silver 
reduction to enhance signal 
~50 Euro 
Gilman K.H. Siu et al., Plos One, Oct 2015 
ID for Gram-positives (agreement 89.6%) ID for Gram-negatives (agreement 90.5%) 
Multicenter study (4 hospitals), 2014 
364 BCs (114 Gram-pos; 250 Gram-neg) 
MDR organisms Time to Results (40-99 hrs faster than routine) 
A. hydrophila, M. morganii, Salmonella spp., A. faecalis, B. pseudomallei, H. influenzae,      
R. planticola, P. putida, S. maltophilia not detectable with the system (n=16; 5.5%) 
K. variicola 80% 
Walker T. et al., J Clin Microbiol; 54:7, 2016 
6-month period before Verigene (n=98) vs. 6-month period after Verigene (n=97) 
Factors associated to length of ICU stay 
Clinical outcome 
Multiv. log. regression for association with 30-d mortality   
Los Angeles 
May 2013 - Nov 2013 
Dec 2014 – May 2015 
Saved 11,661 USD/case 
Inpatient stay = 1,400 USD/day 
ICU stay = 2,800 USD/day 
Test cost (all incl.) = 99 USD 
• Preparation of the pouch  
• Add pouch to FilmArray station (overall, 2 min) 
• Run time of about 1 h 
Pouch (polypropylene) 
Pneumatic system 
Multiplex PCR 
(RT-PCR for RNA target) 
Multiplex real-time PCR  
and Melting analysis 
~100 Euro 
BioFire FilmArray 
Magnetic beads 
Salimnia H.. et al., J Clin Microbiol; 54:3, 2016 
MDR Organisms 
Species ID 
 
8 centers in USA, 2012-2014 
2,207 BC samples 
 - 1,568 clinical 
 - 639 seeded 
R. ornithinolytica 98% 
Intervention group (FilmArray) 
(Aug 2013 – Jan 2014; n=84)  
vs.  
Historical control group  
(Jan 2012 – Jun 2013; n=252) 
Gainesville, Florida 
Pardo J et al., DMID; 84, 2016 
Time to discharge after 
CoNS-contaminated BCs 
Unnecessary vancomycin use 
129 USD for the test 
55% CoNS 
Abbott IRIDICA PCR-ESI MS system 
KPC, VanA, VanB, mecA 
5 mL 
Ibis T5000, Abbott PLEX-ID 
~200-300 Euro 
Metzgar D. et al.,  
PlosOne; July 2016 
Species ID 
Antibiotic R markers 
Johns Hopkins Hospital; Baltimore, USA 
285 whole blood samples (with SIRS) 
Samples processed by Ibis Bioscience 
Limit of detection (LOD) in blood: 16-32 CFU/mL  
273 (95.7%) valid results 
61 negative controls: all negative by IRIDICA 
Organisms detected: IRIDICA, n=85; culture, n=45 
32 out of 40 by culture (80% agreement) 
11 of these 46 pathogens  
gave subsequent infection 
13/13 
T2 Magnetic Resonance (T2MR) 
• Sample transferred to T2Dx (1 min) 
• No extraction/purification  
• Time to results (~3 hrs) 
• Limit of detection: 1 CFU/mL 
T2Bacteria Kit 
 - Gram-negatives: E. coli, K. pneumoniae, P. aeruginosa, A. baumannii 
- Gram-positives: S. aureus, E. faecium 
Accelerate PhenoTM System (BC Kit) 
Gram-positive Gram-negative 
ID: 16 FISH probes AST: morphokinetic cell analysis 
ID: <1.5 hrs 
AST: <7 hrs 
Fully Automated 
Entire process with 1 kit 
2 min to load and start 
Directly from +BC bottle ~120 Euro 
Marschal M et al., JCM, July 2017 
April 2016 – Oct 2016: Southern Germany 
115 BSIs due to Gram-negatives (10 poly) 
Routine: BACTEC 9240, MALDI, Vitek2, Etest 
ACC started on average 8 h after positive signal 
Identification 
Correct ID:  
 102/115 (88.7%) 
Correct ID for covered species: 
 102/105 (97.1%) 
e.g., B. fragilis, M. morganii, H. alvei not detected 
Species ID: 1.35 h – 27.49 hrs before culture-based ID 
AST: 6.65 h – 40.39 hrs earlier than conventional tests  
Check-Direct Screening, Check-Points 
• Rapid preparation  
• Time to results (<3 hrs) 
KPC 
OXA-48-like 
VIM 
NDM 
CTX-M-1 group 
CTX-M-2 group 
CTX-M-9 group 
SHV-ESBL 
Rectal  
swab 
(Copan, ESwab) 
BD MAX Reagent strip 
~30 Euro 
Antonelli et al., DMID, 2016 
Limit of detection (LOD) 
Florence, Italy 
557 rectal swabs 
Summary of the results  
Performance of Check-Direct CPE screening for BD MAX  
ChromID CARBA SMART (w/wo broth enrichment) 
[5 samples not detected] * 
23 KPC 
5 VIM 
1 OXA-48 
TAT from 18-24 hrs (direct culture)  
or 48 hrs (broth enrichment) to 3 hrs 
Culture vs.  C-D direct CPE (2 ≠ master mix) 
Cepheid GeneXpert 
Real-time multiplex PCR 
- Smart fluidic system 
- Filtering and Sonication (DNA) 
- Fluorescent-labeled hybr. probes (6 colors)  
- Internal control 
KPC 
NDM 
OXA-48-like 
VIM 
IMP-1 
MSSA 
MRSA 
CoNS 
 
Targets: spa, mecA and 
junction SCCmec-orfX  
• Add aliquot to elution, vortex, transfer to port S 
• Insert cartridge to station (overall, 1 min) 
• Run time (<1 h) 
~50 Euro 
JCM, 54:7; 2016 
4 centers (2 USA, 1 UK, 1 Spain) 
July 2013 – Feb 2014 
Results obtained in 32-48 min Results by individual targets 
Performance vs. reference method Performance for different targets 
23.5% 
Sensitivity: 96.6% - Specificity: 98.6% 
6 cases of multiple genes (4 not detected by ref. method) 
6 out of 154 specimens not detected by Xpert 
Buchan BW et al., J Clin Microb, 53:3; 2015 
Identification of Staphylococcus aureus 
Identification of MRSA 
Multicenter study (8 hospitals, USA) 
795 BCs (30%, S. aureus; 13% MRSA) 
Statistically  
equivalent 
Statistically  
equivalent 
DiversiLab System: rep-PCR 
~100 Euro 
22-33 strains in one day 
 
Dedicated software 
Online comparison with 
database 
Endimiani A et al., JAC, 2009 
6 hrs 1 h 
Repetitive extragenic palindromic PCR  
OK 
OK 
OK 
OK 
Not good * 
Not good 
Not good 
Not good 
Rapid real-time long read WGS 
(Point of care, POC) 
 
 
Our experience: ~3 hrs for WGS 
Oxford Nanopore Sequencing 
Older  
flow cell 
Rapid 1D kit 
Flow R9 cell 
IJAA, 2014 
~200-300 Euro 
~500 Euro 
UK, 2013-14 
Rectal swabs/clinical samples 
MinION and Illumina 
Clonal? 
Plasmid? 
Tn4401? 
“Integrated automation” 
Robert A. Bonomo and Andrea Endimiani, DMID, 2013 
Rapid, accurate, cost-effective, 
information for treating physicians 
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• Dr. med. Baharak Babouee-Flury (PostDoc) 
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